Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice.
Gretchen L. Eiben(Loyola University Chicago), W. Martin Kast(University of Southern California), Hans Schreiber(University of Chicago), Jeffrey K. Pullen(Pearl River Community College), Larry Smith(Vical (United States)), Markwin P. Velders(Loyola University Chicago), M. Cristina Cassetti
PubMed
October 15, 2002
Cited by 47
Related Papers
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
|Nature Medicine|2002|549
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
|The Journal of Immunology|2001|533